Journal
NATURE REVIEWS CANCER
Volume 12, Issue 2, Pages 89-103Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrc3205
Keywords
-
Categories
Funding
- EU
- Jay and Betty Van Andel Foundation
- Medical Research Council [G0800025] Funding Source: researchfish
- MRC [G0800025] Funding Source: UKRI
Ask authors/readers for more resources
Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of cancer. Genetic and biochemical data have demonstrated that the growth and motility factor hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, the tyrosine kinase MET, have a causal role in all of these processes, thus providing a strong rationale for targeting these molecules in cancer. Parallel progress in understanding the structure and function of HGF/SF, MET and associated signalling components has led to the successful development of blocking antibodies and a large number of small-molecule MET kinase inhibitors. In this Review, we discuss these advances, as well as results from recent clinical studies that demonstrate that inhibiting MET signalling in several types of solid human tumours has major therapeutic value.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available